Detail akcie Oryzon Genomics online

Business Summary: Oryzon Genomics SA, is a Spain-based clinical phase biopharmaceutical company, which discovers and develops drugs based on epigenetics for the treatment of oncological and neurological diseases. Its compounds in clinical development include iadademstat (ORY-lOOl), an LSD1 inhibitor that is in Phase II trials for the treatment of acute myeloid leukemia and small cell lung cancer; and vafidemstat (ORY-2001), an LSD1 inhibitor optimized for the Central Nervous System (CNS), in multiple Phase II clinical trials for the treatment of CNS and psychiatric illnesses. The Company also has ORY-3001, in preclinical development for the treatment of non-oncological diseases and has additional programs to develop inhibitors against other epigenetic targets.
Financial Summary: BRIEF: For the three months ended 31 March 2022, Oryzon Genomics SA revenues was not reported. Net loss decreased 10% to EUR1.6M. Lower net loss reflects Salaries decrease of 39% to EUR791K (expense), Foreign Exchange Gain/Loss - Non-Busines increase from EUR23K to EUR58K (income), Property & Other Taxes decrease of 73% to EUR7K (expense).